Skip to main content

Caris Life Sciences, Inc. (CAI) Stock Analysis

Falling Knife setup

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Biotechnology

Sell if holding. Momentum 3.3/10 is below the 5.0 floor at $15.05 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: MI Profile (84.4%); Negative news sentiment (-0.67).

Caris Life Sciences provides comprehensive molecular profiling and precision medicine solutions focused on oncology, with its MI Profile platform (whole exome and transcriptome sequencing) accounting for 84.4% of 2025 revenue from over 1,000,000 sequenced cases. The company... Read more

$15.05+62.8% A.UpsideScore 6.4/10#9 of 157 Biotechnology
QualityF-score9 / 9FCF yield2.39%
Stop $13.91Target $24.36(analyst − 13%)A.R:R 4.2:1
Analyst target$28.00+86.0%13 analysts
$24.36our TP
$15.05price
$28.00mean
$36

Sell if holding. Momentum 3.3/10 is below the 5.0 floor at $15.05 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: MI Profile (84.4%); Negative news sentiment (-0.67). Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Score 6.4/10, moderate confidence.

Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 85d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.

Val5.8Qual7.2Grw10.0Mom3.3Sent8.0Ins5.3Peer5.6Tech5.7Risk3.76.4OVERALL

Recent Developments — Caris Life Sciences, Inc.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
V7 quality resilience bonus: +0.2 (Q=7.2 in RISK_OFF)
Sector modifier (Healthcare): +0.5
High-quality business
Risks
Concentration risk — Product: MI Profile (84.4%)
Negative news sentiment (-0.67)
Negative momentum

Key Metrics

P/E (TTM)—
P/E (Fwd)40.5
Mkt Cap$4.3B
EV/EBITDA30.1
Profit Mgn3.7%
ROE28.4%
Rev Growth78.8%
Beta—
DividendNone
Rating analysts17

Quality Signals

Piotroski F9/9MoatWideCompounder✓

Options Flow

P/C0.85neutral
IV92%elevated

Concentration Risks(10-K Item 1A)

  • HIGHProductMI Profile84%
    10-K Item 1A: 'MI Profile, our tissue-based profiling solution, which accounted for 84.4% of our revenue for the year ended December 31, 2025'

Material Events(8-K, last 90d)

  • 2026-04-02Item 1.01MEDIUM
    Caris entered $400M initial term loan plus $300M delayed draw credit facility with Blue Owl Capital and Blackstone as lenders, effective April 1, 2026. Unconditionally guaranteed by certain subsidiaries. No reason cited for prior credit arrangement termination.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Ma Position
1.0
Volume
2.1
Rsi
3.5
Obv
10.0
Volume accumulation (rising OBV)Below 200-MA, MA slope -5.2%/30d — confirmed downtrend
GatesMomentum 3.3<4.5Death cross (50MA < 200MA)A.R:R 4.2 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 85d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Aggressive
RSI
38 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $14.19Resistance $21.44

Price Targets

$14
$24
A.Upside+61.9%
A.R:R4.2:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! NEWS_MOD=-1: HOLD_IF_HOLDING → SELL_IF_HOLDING
! Momentum score 3.3/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-08-12 (85d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CAI stock a buy right now?

Sell if holding. Momentum 3.3/10 is below the 5.0 floor at $15.05 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: MI Profile (84.4%); Negative news sentiment (-0.67). Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Prior stop was $13.91. Score 6.4/10, moderate confidence.

What is the CAI stock price target?

Take-profit target: $24.36 (+62.8% upside). Prior stop was $13.91. Stop-loss: $13.91.

What are the risks of investing in CAI?

Concentration risk — Product: MI Profile (84.4%); Negative news sentiment (-0.67); Negative momentum.

Is CAI overvalued or undervalued?

Caris Life Sciences, Inc. trades at a P/E of N/A (forward 40.5). TrendMatrix value score: 5.8/10. Verdict: Sell.

What do analysts say about CAI?

17 analysts cover CAI with a consensus score of 4.2/5. Average price target: $28.

What does Caris Life Sciences, Inc. do?Caris Life Sciences provides comprehensive molecular profiling and precision medicine solutions focused on oncology,...

Caris Life Sciences provides comprehensive molecular profiling and precision medicine solutions focused on oncology, with its MI Profile platform (whole exome and transcriptome sequencing) accounting for 84.4% of 2025 revenue from over 1,000,000 sequenced cases. The company serves oncologists, biopharma partners, and academic centers; Caris Assure and Caris Detect blood-based solutions are under commercialization.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · INCY (Incyte Corporation) · ADMA (ADMA Biologics Inc) · HALO (Halozyme Therapeutics, Inc.) · HRMY (Harmony Biosciences Holdings, I)